These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. 3.0 T magnetic resonance myocardial perfusion imaging for semi-quantitative evaluation of coronary microvascular dysfunction in hypertrophic cardiomyopathy. Yin L; Xu HY; Zheng SS; Zhu Y; Xiao JX; Zhou W; Yu SS; Gong LG Int J Cardiovasc Imaging; 2017 Dec; 33(12):1949-1959. PubMed ID: 28612277 [TBL] [Abstract][Full Text] [Related]
11. Preserved myocardial blood flow in the apical region involved in takotsubo cardiomyopathy by quantitative cardiac PET assessment. Hasbak P; Kjær A; Skovgaard D; Bang LE; Grande P; Holmvang L J Nucl Cardiol; 2012 Feb; 19(1):169-71. PubMed ID: 21892770 [No Abstract] [Full Text] [Related]
12. Complementary role of hybrid imaging with SPECT myocardial perfusion and coronary CT angiography in hypertrophic cardiomyopathy. Abazid RM; Romsa JG; Warrington JC; Akincioglu C; Stodilka RZ; Vezina WC J Nucl Cardiol; 2022 Oct; 29(5):2716-2720. PubMed ID: 33409894 [No Abstract] [Full Text] [Related]
13. Clinical analysis of myocardial perfusion and metabolism in patients with hypertrophic cardiomyopathy by single photon emission tomography and positron emission tomography. Ishida Y; Nagata S; Uehara T; Yasumura Y; Fukuchi K; Miyatake K J Cardiol; 2001; 37 Suppl 1():121-8. PubMed ID: 11433815 [TBL] [Abstract][Full Text] [Related]
14. Direct imaging of myocardial ischaemia with [18F]fluorodeoxyglucose on exercise PET in hypertrophic cardiomyopathy. Yamano M; Kawasaki T; Sugihara H Heart; 2009 Jul; 95(13):1051. PubMed ID: 19525255 [No Abstract] [Full Text] [Related]
15. Marked multi-distribution myocardial ischemia in a patient with hypertrophic cardiomyopathy and no obstructive coronary artery disease. Chan N; Kataria V; Delphin J; Auerbach A; Makaryus JN J Nucl Cardiol; 2020 Apr; 27(2):695-697. PubMed ID: 30719657 [No Abstract] [Full Text] [Related]
16. Higher incidence of vasodilator-induced left ventricular cavity dilation by PET when compared to treadmill exercise-ECHO in hypertrophic cardiomyopathy. Lu DY; Yalçin H; Sivalokanathan S; Greenland GV; Vasquez N; Yalçin F; Zhao M; Valenta I; Ganz P; Pampaloni MH; Zimmerman S; Schindler TH; Abraham TP; Abraham MR J Nucl Cardiol; 2020 Dec; 27(6):2031-2043. PubMed ID: 30456498 [TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinical significance of cardiovascular magnetic resonance adenosine stress-induced myocardial perfusion defect in hypertrophic cardiomyopathy. Kim EK; Lee SC; Chang SA; Jang SY; Kim SM; Park SJ; Choi JO; Park SW; Jeon ES; Choe YH J Cardiovasc Magn Reson; 2020 May; 22(1):30. PubMed ID: 32366254 [TBL] [Abstract][Full Text] [Related]
18. What is this image? 2023 image 2 results: In vivo demonstration of regadenoson-induced severe ischemia on PET myocardial perfusion imaging in a patient with hypertrophic obstructive cardiomyopathy and nonobstructive coronary artery disease. Parizher G; Dugan E; Jaber WA J Nucl Cardiol; 2023 Oct; 30(5):1757-1760. PubMed ID: 37603191 [No Abstract] [Full Text] [Related]
19. Relative Prognostic Significance of Positron Emission Tomography Myocardial Perfusion Imaging Markers in Cardiomyopathy. Thomas M; Sperry BW; Peri-Okonny P; Malik AO; McGhie AI; Saeed IM; Chan PS; Spertus JA; Thompson RC; Bateman TM; Patel KK Circ Cardiovasc Imaging; 2021 Oct; 14(10):e012426. PubMed ID: 34665673 [TBL] [Abstract][Full Text] [Related]
20. Effect of Diffuse Subendocardial Hypoperfusion on Left Ventricular Cavity Size by Yalçin H; Valenta I; Yalçin F; Corona-Villalobos C; Vasquez N; Ra J; Kucukler N; Tahari A; Pozios I; Zhou Y; Pomper M; Abraham TP; Schindler TH; Abraham MR Am J Cardiol; 2016 Dec; 118(12):1908-1915. PubMed ID: 27771003 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]